FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation
about
The secreted protein S100A7 (psoriasin) is induced by telomere dysfunction in human keratinocytes independently of a DNA damage response and cell cycle regulatorsUpregulation of FOXM1 induces genomic instability in human epidermal keratinocytesFOXM1 induces a global methylation signature that mimics the cancer epigenome in head and neck squamous cell carcinomaInduction of human epithelial stem/progenitor expansion by FOXM1The Oncogenic Functions of Nicotinic Acetylcholine ReceptorsThe Role of Forkhead Box Protein M1 in Breast Cancer Progression and Resistance to TherapyPrognostic Value of FOXM1 in Patients with Malignant Solid Tumor: A Meta-Analysis and System ReviewFOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistanceFoxM1: a novel tumor biomarker of lung cancerExploiting FOXM1-orchestrated molecular network for early squamous cell carcinoma diagnosis and prognosisIndependent evaluation of a FOXM1-based quantitative malignancy diagnostic system (qMIDS) on head and neck squamous cell carcinomasPeroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cellsDetection of IGF2BP3, HOXB7, and NEK2 mRNA expression in brush cytology specimens as a new diagnostic tool in patients with biliary strictures.Deletion of Forkhead Box M1 transcription factor from respiratory epithelial cells inhibits pulmonary tumorigenesis.Gene profiling suggests a common evolution of bladder cancer subtypesCancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and Prognosis of Prostate and Other CancersFOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patientsEPS8 upregulates FOXM1 expression, enhancing cell growth and motilityAberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells.Nicotine: specific role in angiogenesis, proliferation and apoptosis.FoxM1 is a novel target of a natural agent in pancreatic cancer.Two mechanisms regulate keratin K15 expression in keratinocytes: role of PKC/AP-1 and FOXM1 mediated signalling.Nicotine promotes acquisition of stem cell and epithelial-to-mesenchymal properties in head and neck squamous cell carcinoma.Up-regulation of FOXM1 by E6 oncoprotein through the MZF1/NKX2-1 axis is required for human papillomavirus-associated tumorigenesis.Sub-sets of cancer stem cells differ intrinsically in their patterns of oxygen metabolism.Nicotinic acetylcholine receptor signaling in tumor growth and metastasisProteasome inhibitors in cancer therapyMultiple faces of FoxM1 transcription factor: lessons from transgenic mouse models.From smoking to cancers: novel targets to neuronal nicotinic acetylcholine receptors.Developmental toxicity assay using high content screening of zebrafish embryos.Treatment of breast cancer cells with DNA demethylating agents leads to a release of Pol II stalling at genes with DNA-hypermethylated regions upstream of TSS.The 26S proteasome complex: an attractive target for cancer therapyCentrosomal protein 55 (Cep55) stability is negatively regulated by p53 protein through Polo-like kinase 1 (Plk1)Nucleophosmin interacts with FOXM1 and modulates the level and localization of FOXM1 in human cancer cells.7-difluoromethoxyl-5,4'-di-n-octylgenistein inhibits growth of gastric cancer cells through downregulating forkhead box M1.Possibility of the use of public microarray database for identifying significant genes associated with oral squamous cell carcinomaFOXM1b, which is present at elevated levels in cancer cells, has a greater transforming potential than FOXM1c.Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cellsUpregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinomaRecently identified biomarkers that promote lymph node metastasis in head and neck squamous cell carcinoma
P2860
Q54971036-5F964358-038A-4EC5-A6FB-EE52BA0FACE7Q54971037-A49359BF-FB3A-4DB8-AF89-3B5E4555E560Q54971039-F313EDD9-0C41-4FAB-9AC7-D6FC39BFF530Q54971040-B7FB5AE4-41BC-44B6-A2A5-C8070559CD9AQ54971041-2F96CE11-B061-445F-8A4D-FE9E6EEDF8BEQ54971042-655FDB65-D919-4E20-ACAC-D85DFA50B878Q54971043-84B8F437-3DFF-433E-B69E-64B3137DEB6FQ54971044-F910D11B-95BC-4E2A-BA6F-073D785E06CAQ54971045-79135BB2-6C5E-4076-AEAC-2129ED38C7B3
P1343
Q21195847-B257D60B-23BE-4738-A76C-1C5EFC78B537Q21245703-E4DF1585-303C-4C96-8E9D-0CA45CE3A535Q21561022-1DFC4A93-CFD0-4EC6-8299-210C2E9F1503Q24615565-6A0C48EC-BF1B-4A57-A8D0-622061B62B49Q26765286-9ABA1428-2250-4472-94E5-B7AF481122FFQ26768290-66E0C35B-BAEB-4811-A440-6C541299B5EAQ26785676-0AE11B59-80F6-472A-9F77-06362AACDC03Q26864654-3885A07F-4C71-4D46-BC1D-5D3FE4A419AFQ28081689-3FBC58D4-C1B0-4C55-8A58-186A7DCCC15FQ28276344-EA379406-B53D-4BE3-813E-ED88F8B6BFE9Q28277102-03B4BBA9-EF99-4883-B01B-621EC2FAFF88Q28728015-6AFF2B5E-AA9E-4899-AE6C-C2A479A4606CQ31081531-5F3A5777-7D82-48E2-9A25-E8EFF3967503Q33492769-0FFFB3EC-0467-436B-89E7-0A07735E49E1Q33589389-7D5AE50D-9351-42DE-90F0-89E2E13AB7EEQ33624448-1E62220A-C43E-4B90-9622-0BA3EEC63A88Q33651605-00C30F8A-A327-4071-899C-2407B1E0E8CCQ33884598-A7F910CF-965C-4BC3-9F51-E4BC2CCB4465Q34000057-C4BCD871-B1CC-4E82-9F94-82CE09A69F7AQ34229828-308B653E-4C39-4690-8B43-3C148C477C01Q34286063-15A4A76A-A680-4000-BA7B-0C4A95A9281FQ34325739-410418B0-5650-44F7-AB32-6AD759413AE2Q34540328-86B03D67-40F7-4FC1-9F8C-FA9E7E0DF8F7Q34558924-1536F4A9-BC2E-4311-A577-88BD301A395BQ34701603-0BE19603-DEE4-4134-AD2A-34D3F8129F2FQ34896088-474EC546-DA7F-4437-B968-DC51907FEC72Q34939959-BB2F284C-D273-4A92-98EB-F370DF39BEB4Q35045311-AF9464BF-4BCB-4AD1-95F3-462F444937B7Q35104827-0AA5E473-7203-4C48-858F-AEE9AF7C3836Q35175595-56AB729B-CBA9-464B-ACB8-4C1CDECB2228Q35617265-B6962845-CEC0-4204-A40E-85D3DA5E812AQ35624079-7ACD2B63-DA2C-40BD-8820-62ED7E1148AAQ35763224-58880ED2-841C-4A92-892D-56210AB654FEQ35842155-E0CEF3B0-A2CA-4210-810F-5C82B66A5105Q36214636-730A7799-15A5-4371-B528-A953EA63D72FQ36330529-190550EC-94A0-4EC0-AF2E-B1CFD9D12BAEQ36576225-5B700D43-6347-4CC9-9152-4D721D7C1D18Q36883777-03D7A963-7F11-4DE4-B244-AF811588B98FQ36922664-23FB7ED5-48C6-416F-A5F6-903F169F21DAQ37129819-4BAF492C-F0CC-41F2-9A9A-CF6B213B74FE
P2860
FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
FOXM1 upregulation is an early ...... uring malignant transformation
@ast
FOXM1 upregulation is an early ...... uring malignant transformation
@en
FOXM1 upregulation is an early ...... uring malignant transformation
@en-gb
FOXM1 upregulation is an early ...... uring malignant transformation
@nl
type
label
FOXM1 upregulation is an early ...... uring malignant transformation
@ast
FOXM1 upregulation is an early ...... uring malignant transformation
@en
FOXM1 upregulation is an early ...... uring malignant transformation
@en-gb
FOXM1 upregulation is an early ...... uring malignant transformation
@nl
altLabel
FOXM1 Upregulation Is an Early ...... uring Malignant Transformation
@en
prefLabel
FOXM1 upregulation is an early ...... uring malignant transformation
@ast
FOXM1 upregulation is an early ...... uring malignant transformation
@en
FOXM1 upregulation is an early ...... uring malignant transformation
@en-gb
FOXM1 upregulation is an early ...... uring malignant transformation
@nl
P2093
P2860
P4510
P921
P1433
P1476
FOXM1 upregulation is an early ...... uring malignant transformation
@en
P2093
Adeel M Riaz
Ahmad Waseem
Amrita Bose
Bryan D Young
David Sugden
Emilios Gemenetzidis
Eric K Parkinson
Farida Fortune
Johanna K Thurlow
P2860
P356
10.1371/JOURNAL.PONE.0004849
P407
P4510
P50
P577
2009-01-01T00:00:00Z